Tesamorelin

Description

Introduction

Tesamorelin is used to reduce excess fat around the stomach that is caused by taking certain HIV medications. This condition is also called lipodystrophy (LYE-poe-DIS-troe-ee). Tesamorelin is not a weight-loss medication and should not be used to treat obesity.

Editor’s Note: You can buy “Tesamorelin” from our top recommended source.

How it works?

In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF.

Growth Hormone-Releasing Factor (GRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic. GH exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all these effects, are primarily mediated by IGF-1 produced in the liver and in peripheral tissues.

Side Effects

Redness, itching, pain, irritation, or bruising at the injection site may occur. Muscle aches may also occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
This medication may rarely make your blood sugar rise, which can cause or worsen diabetes. Tell your doctor right away if you have symptoms of high blood sugar such as increased thirst/urination. If you already have diabetes, check your blood sugar regularly as directed and share the results with your doctor. Your doctor may need to adjust your diabetes medication, exercise program, or diet.

More information

You should not use tesamorelin if you are allergic to it, or if you have:
● cancer;
● a pituitary gland disorder;
● history of pituitary gland tumor or surgery;
● a history of head injury or radiation treatment; or if you are pregnant.

Dosage

The recommended dose of Tesamorelin is 2 mg injected subcutaneously once a day.

The recommended injection site is the abdomen. Injection sites should be rotated to different areas of the abdomen. Do not inject into scar tissue, bruises or the navel.

Conclusion

Tesamorelin reduces visceral fat by approximately 18% and improves body image distress in HIV-infected patients with central fat accumulation. These changes are achieved without significant side effects or perturbation of glucose

User reviews

Review 1
“I have been on Egrifta for 14 months. It took 6 months before I noticed much. I am now pleased with the results and will continue to use the product.”

Review 2
I began the injection of 2 mg daily and after week one I noticed that my stomach was beginning to soften. Now nearly a month into this medication I have come down 12 lbs and seem to be holding there. I hope it and pray it gets me back to where I should be.”

Review 3

Egrifta (tesamorelin) for Lipodystrophy: “I have used Egrifta for about 4 years now, except when the drug was not available. I had a reduction in belly fat to a great degree AND lost over 25 lbs. I tapered the drug when I got too thin and stopped for over 9 months due to drug not being available. I believe I have also seen more fat in my face where it wasted before. I started again about 1 year ago when I started gaining weight (but more the old way)Now in the last 6 months my belly is still soft as oppposed to hard before the drug but still gaining weight so I have been dieting. Anyone else seeing similar or different longer term effects?”